Atorvastatin treatment does not abolish inflammatory mediated cardiovascular risk in subjects with chronic kidney disease

Abstract Individuals with chronic kidney disease are at an increased risk for cardiovascular disease. This risk may partially be explained by a chronic inflammatory state in these patients, reflected by increased arterial wall and cellular inflammation. Statin treatment decreases cardiovascular risk...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Renate M. Hoogeveen, Simone L. Verweij, Yannick Kaiser, Jeffrey Kroon, Hein J. Verberne, Liffert Vogt, Sophie J. Bernelot Moens, Erik S. G. Stroes
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/5c18abc477fa4ebbbdfb11d89e5dbb97
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5c18abc477fa4ebbbdfb11d89e5dbb97
record_format	dspace
spelling	oai:doaj.org-article:5c18abc477fa4ebbbdfb11d89e5dbb972021-12-02T14:21:53ZAtorvastatin treatment does not abolish inflammatory mediated cardiovascular risk in subjects with chronic kidney disease10.1038/s41598-021-83273-22045-2322https://doaj.org/article/5c18abc477fa4ebbbdfb11d89e5dbb972021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-83273-2https://doaj.org/toc/2045-2322Abstract Individuals with chronic kidney disease are at an increased risk for cardiovascular disease. This risk may partially be explained by a chronic inflammatory state in these patients, reflected by increased arterial wall and cellular inflammation. Statin treatment decreases cardiovascular risk and arterial inflammation in non-CKD subjects. In patients with declining kidney function, cardiovascular benefit resulting from statin therapy is attenuated, possibly due to persisting inflammation. In the current study, we assessed the effect of statin treatment on arterial wall and cellular inflammation. Fourteen patients with chronic kidney disease stage 3 or 4, defined by an estimated Glomerular Filtration Rate between 15 and 60 mL/min/1.73 m2, without cardiovascular disease were included in a single center, open label study to assess the effect of atorvastatin 40 mg once daily for 12 weeks (NTR6896). At baseline and at 12 weeks of treatment, we assessed arterial wall inflammation by 18F-fluoro-deoxyglucose positron-emission tomography computed tomography (18F-FDG PET/CT) and the phenotype of circulating monocytes were assessed. Treatment with atorvastatin resulted in a 46% reduction in LDL-cholesterol, but this was not accompanied by an attenuation in arterial wall inflammation in the aorta or carotid arteries, nor with changes in chemokine receptor expression of circulating monocytes. Statin treatment does not abolish arterial wall or cellular inflammation in subjects with mild to moderate chronic kidney disease. These results imply that CKD-associated inflammatory activity is mediated by factors beyond LDL-cholesterol and specific anti-inflammatory interventions might be necessary to further dampen the inflammatory driven CV risk in these subjects.Renate M. HoogeveenSimone L. VerweijYannick KaiserJeffrey KroonHein J. VerberneLiffert VogtSophie J. Bernelot MoensErik S. G. StroesNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Renate M. Hoogeveen Simone L. Verweij Yannick Kaiser Jeffrey Kroon Hein J. Verberne Liffert Vogt Sophie J. Bernelot Moens Erik S. G. Stroes Atorvastatin treatment does not abolish inflammatory mediated cardiovascular risk in subjects with chronic kidney disease
description	Abstract Individuals with chronic kidney disease are at an increased risk for cardiovascular disease. This risk may partially be explained by a chronic inflammatory state in these patients, reflected by increased arterial wall and cellular inflammation. Statin treatment decreases cardiovascular risk and arterial inflammation in non-CKD subjects. In patients with declining kidney function, cardiovascular benefit resulting from statin therapy is attenuated, possibly due to persisting inflammation. In the current study, we assessed the effect of statin treatment on arterial wall and cellular inflammation. Fourteen patients with chronic kidney disease stage 3 or 4, defined by an estimated Glomerular Filtration Rate between 15 and 60 mL/min/1.73 m2, without cardiovascular disease were included in a single center, open label study to assess the effect of atorvastatin 40 mg once daily for 12 weeks (NTR6896). At baseline and at 12 weeks of treatment, we assessed arterial wall inflammation by 18F-fluoro-deoxyglucose positron-emission tomography computed tomography (18F-FDG PET/CT) and the phenotype of circulating monocytes were assessed. Treatment with atorvastatin resulted in a 46% reduction in LDL-cholesterol, but this was not accompanied by an attenuation in arterial wall inflammation in the aorta or carotid arteries, nor with changes in chemokine receptor expression of circulating monocytes. Statin treatment does not abolish arterial wall or cellular inflammation in subjects with mild to moderate chronic kidney disease. These results imply that CKD-associated inflammatory activity is mediated by factors beyond LDL-cholesterol and specific anti-inflammatory interventions might be necessary to further dampen the inflammatory driven CV risk in these subjects.
format	article
author	Renate M. Hoogeveen Simone L. Verweij Yannick Kaiser Jeffrey Kroon Hein J. Verberne Liffert Vogt Sophie J. Bernelot Moens Erik S. G. Stroes
author_facet	Renate M. Hoogeveen Simone L. Verweij Yannick Kaiser Jeffrey Kroon Hein J. Verberne Liffert Vogt Sophie J. Bernelot Moens Erik S. G. Stroes
author_sort	Renate M. Hoogeveen
title	Atorvastatin treatment does not abolish inflammatory mediated cardiovascular risk in subjects with chronic kidney disease
title_short	Atorvastatin treatment does not abolish inflammatory mediated cardiovascular risk in subjects with chronic kidney disease
title_full	Atorvastatin treatment does not abolish inflammatory mediated cardiovascular risk in subjects with chronic kidney disease
title_fullStr	Atorvastatin treatment does not abolish inflammatory mediated cardiovascular risk in subjects with chronic kidney disease
title_full_unstemmed	Atorvastatin treatment does not abolish inflammatory mediated cardiovascular risk in subjects with chronic kidney disease
title_sort	atorvastatin treatment does not abolish inflammatory mediated cardiovascular risk in subjects with chronic kidney disease
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/5c18abc477fa4ebbbdfb11d89e5dbb97
work_keys_str_mv	AT renatemhoogeveen atorvastatintreatmentdoesnotabolishinflammatorymediatedcardiovascularriskinsubjectswithchronickidneydisease AT simonelverweij atorvastatintreatmentdoesnotabolishinflammatorymediatedcardiovascularriskinsubjectswithchronickidneydisease AT yannickkaiser atorvastatintreatmentdoesnotabolishinflammatorymediatedcardiovascularriskinsubjectswithchronickidneydisease AT jeffreykroon atorvastatintreatmentdoesnotabolishinflammatorymediatedcardiovascularriskinsubjectswithchronickidneydisease AT heinjverberne atorvastatintreatmentdoesnotabolishinflammatorymediatedcardiovascularriskinsubjectswithchronickidneydisease AT liffertvogt atorvastatintreatmentdoesnotabolishinflammatorymediatedcardiovascularriskinsubjectswithchronickidneydisease AT sophiejbernelotmoens atorvastatintreatmentdoesnotabolishinflammatorymediatedcardiovascularriskinsubjectswithchronickidneydisease AT eriksgstroes atorvastatintreatmentdoesnotabolishinflammatorymediatedcardiovascularriskinsubjectswithchronickidneydisease
_version_	1718391487420432384

Atorvastatin treatment does not abolish inflammatory mediated cardiovascular risk in subjects with chronic kidney disease

Ejemplares similares